Virios Therapeutics (VIRI) Competitors $4.37 +0.02 (+0.46%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends VIRI vs. AKBA, CYRX, ZVRA, AMLX, YSB, JSPR, LXEO, BTMD, ACB, and RZLTShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Akebia Therapeutics (AKBA), Cryoport (CYRX), Zevra Therapeutics (ZVRA), Amylyx Pharmaceuticals (AMLX), YS Biopharma (YSB), Jasper Therapeutics (JSPR), Lexeo Therapeutics (LXEO), biote (BTMD), Aurora Cannabis (ACB), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Akebia Therapeutics Cryoport Zevra Therapeutics Amylyx Pharmaceuticals YS Biopharma Jasper Therapeutics Lexeo Therapeutics biote Aurora Cannabis Rezolute Virios Therapeutics (NASDAQ:VIRI) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation. Does the MarketBeat Community prefer VIRI or AKBA? Akebia Therapeutics received 411 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 64.19% of users gave Akebia Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Akebia TherapeuticsOutperform Votes41464.19% Underperform Votes23135.81% Which has stronger valuation & earnings, VIRI or AKBA? Virios Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-16.19Akebia Therapeutics$194.62M1.83-$51.92M-$0.21-8.05 Do institutionals and insiders hold more shares of VIRI or AKBA? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is VIRI or AKBA more profitable? Virios Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -23.18%. Akebia Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Akebia Therapeutics -23.18%N/A -17.54% Do analysts recommend VIRI or AKBA? Virios Therapeutics currently has a consensus price target of $3.00, indicating a potential downside of 31.35%. Akebia Therapeutics has a consensus price target of $5.75, indicating a potential upside of 240.24%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, VIRI or AKBA? Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Does the media refer more to VIRI or AKBA? In the previous week, Akebia Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for Akebia Therapeutics and 2 mentions for Virios Therapeutics. Akebia Therapeutics' average media sentiment score of 0.73 beat Virios Therapeutics' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAkebia Therapeutics beats Virios Therapeutics on 13 of the 17 factors compared between the two stocks. Ad Behind the MarketsA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.Click here to get the ticker >>> Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.16M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-16.199.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book21.855.324.665.02Net Income-$5.30M$153.56M$119.06M$225.46M7 Day Performance-12.42%0.13%0.80%0.37%1 Month Performance2,646.70%15.23%5.65%3.57%1 Year Performance439.37%41.14%36.75%29.43% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios Therapeutics0.1482 of 5 stars$4.37+0.5%$3.00-31.4%+747.9%$84.16MN/A-16.195Gap DownAKBAAkebia Therapeutics4.0426 of 5 stars$1.71+4.9%$5.75+236.3%+91.6%$358.41M$174.50M-8.14167Short Interest ↓News CoverageCYRXCryoport2.515 of 5 stars$7.19+0.1%$12.00+66.9%-24.9%$354.16M$225.61M-1.961,170Upcoming EarningsShort Interest ↑News CoverageZVRAZevra Therapeutics2.9026 of 5 stars$8.26+2.6%$20.83+152.2%+88.8%$345.71M$23.69M-4.9265Upcoming EarningsPositive NewsAMLXAmylyx Pharmaceuticals4.0918 of 5 stars$5.07-4.9%$14.57+187.4%-67.0%$344.79M$298.76M-2.07200Positive NewsYSBYS Biopharma1.4561 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773JSPRJasper Therapeutics3.4255 of 5 stars$22.46+2.0%$74.86+233.3%+210.4%$338.34MN/A-4.4020LXEOLexeo Therapeutics3.195 of 5 stars$9.95+1.2%$22.14+122.5%N/A$328.96M$650,000.00-0.6858Analyst ForecastNews CoverageBTMDbiote3.9719 of 5 stars$5.23-0.2%$8.39+60.4%-1.9%$324.45M$187.23M30.76194Short Interest ↓ACBAurora Cannabis0.7297 of 5 stars$5.90-0.8%N/A+22.3%$321.82M$278.98M-8.431,073Upcoming EarningsRZLTRezolute3.7018 of 5 stars$5.68+0.9%$11.57+103.7%+436.6%$317.67MN/A-4.2740News Coverage Related Companies and Tools Related Companies Akebia Therapeutics Alternatives Cryoport Alternatives Zevra Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives YS Biopharma Alternatives Jasper Therapeutics Alternatives Lexeo Therapeutics Alternatives biote Alternatives Aurora Cannabis Alternatives Rezolute Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts